Our response rate was 26%. Neurologists asked for representative experts’ visits for more information concerning the Nubrenza patches and to get familiar with more cases of success. 80% of our target perceived that with Nubrenza Patches patients would be able to improve motor efficiency in the early stages of Parkinson’s disease. The importance of treatment of the non-motor symptoms of Parkinson’s disease as essential increased to 56% of our target.